SELLAS Life Sciences Reports Strong Cash Position and Imminent Phase 3 Trial Results
SLS has more than doubled off its 52-week low of $0.952.
Summary
SELLAS Life Sciences announced full year 2025 financial results, reporting a significantly strengthened cash position and providing positive updates on its key clinical programs, including the imminent final analysis of its Phase 3 REGAL trial.
Key Events · Earnings and Guidance · SLS
-
Strengthened Financial Position
The company reported $71.8 million in cash and cash equivalents as of December 31, 2025, with an additional $42.6 million received from warrant exercises in Q1 2026, bringing total cash to $114.4 million and extending its operational runway beyond 12 months.
-
Phase 3 REGAL Trial Nearing Final Analysis
The pivotal Phase 3 REGAL trial for Galinpepimut-S (GPS) in AML has recorded 72 out of the pre-specified 80 events, indicating that topline results are imminent upon reaching the final event and completing data procedures.
-
SLS009 Clinical Program Expansion
Following positive Phase 2 results in relapsed/refractory AML, the company has dosed the first patient in an 80-patient trial for SLS009 in newly diagnosed, first-line AML patients and entered a European collaboration to expand the program.
Analysis · SLS · Life Sciences
SELLAS Life Sciences reported full year 2025 financial results, highlighting a significantly strengthened cash position of $71.8 million as of December 31, 2025, further bolstered by an additional $42.6 million from warrant exercises in Q1 2026. This provides the company with its strongest financial position in history, extending its operational runway beyond 12 months. The filing also provides a critical update on the pivotal Phase 3 REGAL trial for GPS in AML, which is nearing its final analysis with 72 out of 80 required events recorded. Positive Phase 2 data for SLS009 in r/r AML and its expansion into first-line AML treatment, including a new European collaboration, further underscore the company's pipeline progress. These developments collectively reduce near-term financial risk and set the stage for major clinical catalysts.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1052 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLS was trading at $5.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $740.7M. The 52-week trading range was $0.95 to $6.14. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.